Forty Seven (NASDAQ: FTSV) is one of 555 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Forty Seven to similar businesses based on the strength of its dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Institutional and Insider Ownership
43.7% of Forty Seven shares are owned by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 37.4% of Forty Seven shares are owned by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Forty Seven and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Forty Seven Competitors||-1,566.06%||-828.31%||-27.99%|
This is a breakdown of recent recommendations and price targets for Forty Seven and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Forty Seven Competitors||4727||13406||28187||1020||2.54|
Forty Seven currently has a consensus price target of $27.71, indicating a potential upside of 130.19%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.87%. Given Forty Seven’s stronger consensus rating and higher probable upside, equities analysts clearly believe Forty Seven is more favorable than its competitors.
Earnings and Valuation
This table compares Forty Seven and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Forty Seven||N/A||-$70.37 million||-3.21|
|Forty Seven Competitors||$2.14 billion||$224.95 million||-3.93|
Forty Seven’s competitors have higher revenue and earnings than Forty Seven. Forty Seven is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Forty Seven beats its competitors on 7 of the 12 factors compared.
About Forty Seven
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.